Your browser is no longer supported. Please, upgrade your browser.
DMAC DiaMedica Therapeutics Inc. monthly Stock Chart
DMAC [NASD]
DiaMedica Therapeutics Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own1.20% Shs Outstand16.69M Perf Week34.66%
Market Cap108.39M Forward P/E- EPS next Y-0.72 Insider Trans8.13% Shs Float16.43M Perf Month38.89%
Income-10.60M PEG- EPS next Q-0.17 Inst Own39.00% Short Float0.19% Perf Quarter26.65%
Sales- P/S- EPS this Y-20.00% Inst Trans99.85% Short Ratio0.42 Perf Half Y23.92%
Book/sh1.78 P/B3.23 EPS next Y- ROA-62.90% Target Price- Perf Year57.53%
Cash/sh1.62 P/C3.54 EPS next 5Y- ROE-68.20% 52W Range1.87 - 8.80 Perf YTD18.56%
Dividend- P/FCF- EPS past 5Y13.60% ROI- 52W High-34.66% Beta1.96
Dividend %- Quick Ratio21.60 Sales past 5Y- Gross Margin- 52W Low207.49% ATR0.38
Employees8 Current Ratio21.60 Sales Q/Q- Oper. Margin- RSI (14)75.38 Volatility11.66% 8.07%
OptionableNo Debt/Eq0.00 EPS Q/Q6.20% Profit Margin- Rel Volume6.31 Prev Close5.58
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume76.95K Price5.75
Recom- SMA2030.33% SMA5031.25% SMA20024.35% Volume485,275 Change3.05%
Oct-30-20Initiated Guggenheim Buy $16
Jul-08-20Initiated Maxim Group Buy $14
Apr-30-19Initiated Dougherty & Company Buy $8
Mar-05-19Initiated Lake Street Buy $9
Nov-24-20 09:46AM  
Nov-19-20 09:04AM  
Nov-11-20 08:30AM  
Nov-10-20 11:22AM  
Nov-05-20 06:15AM  
Nov-04-20 04:30PM  
Oct-28-20 08:30AM  
Oct-01-20 03:30PM  
Sep-15-20 08:15AM  
Sep-14-20 09:15AM  
Aug-11-20 04:05PM  
Aug-10-20 04:05PM  
Aug-06-20 04:05PM  
09:05AM  
Aug-05-20 04:01PM  
Jun-10-20 08:16PM  
May-19-20 04:42PM  
May-13-20 04:41PM  
04:40PM  
May-07-20 04:30PM  
Mar-26-20 09:12AM  
Mar-24-20 06:00AM  
Mar-23-20 04:35PM  
Mar-22-20 02:25PM  
Mar-17-20 08:10AM  
Mar-09-20 08:10AM  
Feb-13-20 04:35PM  
Feb-11-20 07:15AM  
Dec-23-19 02:32PM  
Dec-17-19 04:14PM  
Nov-13-19 04:12PM  
Nov-06-19 04:04PM  
Nov-05-19 04:04PM  
Oct-14-19 07:42AM  
Sep-06-19 09:00AM  
Sep-03-19 04:15PM  
Aug-13-19 04:35PM  
Aug-12-19 08:00AM  
Aug-08-19 04:00PM  
Jun-21-19 07:18AM  
Jun-20-19 07:25AM  
Jun-19-19 04:04PM  
May-21-19 08:34AM  
May-14-19 06:00AM  
May-13-19 04:48PM  
May-06-19 08:54AM  
Apr-30-19 04:58PM  
Mar-19-19 04:30PM  
Mar-18-19 01:56PM  
Mar-12-19 01:00PM  
Feb-14-19 08:00AM  
Jan-22-19 07:45AM  
Jan-16-19 04:00PM  
Jan-10-19 08:27AM  
Jan-09-19 05:00PM  
Jan-03-19 10:41AM  
Dec-02-18 05:01PM  
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Giuffre Randall MichaelDirectorNov 20Buy4.2615,00063,912108,588Nov 23 04:22 PM
Kellen ScottCFO and SecretaryNov 09Buy4.192,0008,38712,290Nov 10 08:16 AM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.